Evidence mapPaperPMID 40813684Full record

ArticleDiabetology & metabolic syndrome2025

Carotenoid and peptide supplementation from Caulerpa sp. (sea grapes) extract mitigate metabolic syndrome in cholesterol-enriched diet rats via modulation of gut microbiota.

Rudy Kurniawan, Fahrul Nurkolis, Agussalim Bukhari, Andi Yasmin Syauki, Burhanudin Bahar, Andi Makbul Aman, Nurpudji Astuti Taslim

Abstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rudy KurniawanGraduate School of Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Fahrul NurkolisMaster of Basic Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Agussalim BukhariDivision of Clinical Nutrition, Department of Nutrition, Faculty of Medicine, Hasanuddin University, Makassar, 90245, Indonesia.
Andi Yasmin SyaukiDivision of Clinical Nutrition, Department of Nutrition, Faculty of Medicine, Hasanuddin University, Makassar, 90245, Indonesia.
Burhanudin BaharDepartment of Nutrition Sciences, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia.
Andi Makbul AmanDepartment of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Nurpudji Astuti TaslimDivision of Clinical Nutrition, Department of Nutrition, Faculty of Medicine, Hasanuddin University, Makassar, 90245, Indonesia. pudji_taslim@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic syndrome (MetS) is a multifactorial disorder characterized by obesity, dyslipidemia, insulin resistance, and hypertension, increasing the risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM). Recent evidence suggests that gut microbiome dysbiosis plays a significant role in MetS pathogenesis. Functional foods enriched with bioactive compounds, particularly those derived from marine sources, have emerged as promising interventions.

objectiveThis study aimed to evaluate the effects of carotenoid and peptide supplementation from Caulerpa sp. (sea grapes) extract on metabolic syndrome and gut microbiome modulation in cholesterol-fat-enriched diet (CFED) rats.

methodsA randomized preclinical trial was conducted using CFED-fed rats, supplemented with carotenoid and peptide extracts from Caulerpa sp. Metabolic parameters, lipid profiles, enzymatic activities, and inflammatory biomarkers were assessed. Additionally, gut microbiota composition was analyzed using high-throughput sequencing techniques.

resultsSupplementation with Caulerpa sp. extracts significantly improved metabolic markers, including reductions in body weight gain, triglycerides, total cholesterol, low-density lipoprotein (LDL), and blood glucose levels, while increasing high-density lipoprotein (HDL) (p < 0.05). Enzymatic analysis revealed suppression of key metabolic enzymes, such as α-glucosidase and lipase, suggesting potential regulatory effects on lipid and carbohydrate metabolism. Moreover, gut microbiome analysis indicated increased microbial diversity and favorable shifts in bacterial taxa. Specifically, Faecalibacterium and Lactobacillus, known for their anti-inflammatory and metabolic benefits, were enriched, while Oscillospira, which has been associated with metabolic disorders, showed a decline. These microbial changes suggest a potential role of Caulerpa sp. in modulating gut health and systemic metabolism.

conclusionThe findings demonstrate that carotenoid and peptide extracts from Caulerpa sp. effectively mitigate metabolic syndrome through metabolic regulation, gut microbiome modulation, and anti-inflammatory mechanisms. This study highlights Caulerpa sp. as a potential functional food for MetS management, paving the way for future clinical applications. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

DiabetesFunctional foodGreen algaeGut microbiotaMetabolic syndromeObesity

Identifiers

PMID40813684
PMCPMC12351937

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.